Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 25Active not recruiting 17Not yet recruiting 3Withdrawn 2Terminated 2Completed 2Enrolling by invitation 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 64Magnetic Resonance Spectroscopy 44Carboplatin 34Cyclophosphamide 31Gemcitabine 29Biopsy 28Cisplatin 27Radiotherapy 26pembrolizumab 25Bevacizumab 25Paclitaxel 23Standard of Care 22Oxaliplatin 22Drug Therapy 22venetoclax 21Nivolumab 21Capecitabine 21fludarabine 20Injections 20Interviews as Topic 18Radiosurgery 16Dexamethasone 16Blood Specimen Collection 16Azacitidine 16toripalimab 15tislelizumab 14cemiplimab 13anlotinib 13Irinotecan 13Pemetrexed 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × sacituzumab govitecan × 90 days × Clear all
NCT07504588 2026-06-03

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
87 enrolled
Gynecologic

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07178730 2026-05-06

ADAPT-TN-IV

West German Study Group

Phase 3 Not yet recruiting
765 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07438600 2026-03-27

TianjinCIH

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
38 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡